EyeCRO scientists contribute to study published in Experimental Eye Research
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Intravitreal administration of small molecule read-through agents demonstrate functional activity in a nonsense mutation mouse model.
Global pharmaceutical company Allergan (NYSE:AGN) may have just revealed its plans for the future. On Aug. 11, the company announced its plan to acquire ForSight Vision5, a privately held biotech. Allergan will pay $95 million up front and will also pay a milestone payment next year if ForSight’s innovative glaucoma treatment device makes it through the…
Retinitis pigmentosa, a blinding eye disease that is caused by the same genetic defect in both dogs and humans, was successfully corrected by a University of Pennsylvania research team that used gene therapy in afflicted dogs. The retinitis pigmentosa cure holds promise for eventual treatment in humans as well. Both humans and dogs can contract…
The promising clinical results obtained for ocular gene therapy in recent years have paved the way for gene supplementation to treat recessively inherited forms of retinal degeneration. We used spliceosome-mediated RNA trans-splicing as a strategy for repairing the transcript of the rhodopsin gene, the gene most frequently mutated in autosomal dominant retinitis pigmentosa (RP). Retinitis…
Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization Click here to read more
Inhalable and thermo-responsive, fat-encased nanoparticles have been developed by researchers at the University of Sydney as possible treatment for lung cancer. The team has recently designed inhalable, targetable particles that can attack tumors but leave healthy cells undamaged, reducing the side effects of cancer treatment. The particles consist of a drug encased in a lipid…
A contact lens with a built-in sensor could help determine which glaucoma patients have a higher risk of disease progression, according to a new study. Glaucoma remains a leading cause of blindness. One of the main indicators of the disease is high pressure in the eye, or intraocular pressure. Researchers at Columbia tested the lenses on…
Locations
Oklahoma City — Headquarters
5301 N. Beverly Drive
Oklahoma City, OK 73105
Ann Arbor
2725 S. Industrial Hwy, Suite 150
Ann Arbor, MI 48104
Credentials
Signatory
© 2026 EyeCRO. All rights reserved.
eyecro.com